Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
TOP STORIES — Diabetes News and Research
Oral Semaglutide – A Phase 3 Trial in Patients with Type 2 Diabetes
Liraglutide Linked to Gallbladder Complications
The Risk of Undiagnosed CKD In Patients with Type 2 Diabetes
MOST POPULAR ARTICLES OF THE MONTH
#1 Updated Consensus Report on Diabetic Nutrition Therapy
#2 Intermittent Fasting Beneficial for Weight Loss and Glycemic Control
#3 Predicting Diabetes Diagnoses Using Random Plasma Glucose
Editor's Note
This week the FDA approved the oral GLP-1 analog, semaglutide (Rybelus) for the treatment of type 2 diabetes. This is the first oral medication in the class that includes liraglutide, exenatide and dulaglutide. The secret of making this work orally is a medium chain fatty acid, and our intern Nour Salhab, Pharm.D. Candidate, USF College of Pharmacy, has found what that fatty acid is and examined the results that led to the groundbreaking new medication.
Dave Joffe
Editor-in-chief
TOP STORIES -- Diabetes News and Research
Final results from a phase 3 study preceded FDA approval of oral semaglutide.
A secondary analysis of the LEADER trial to investigate the safety of liraglutide in patients with type 2 diabetes.
Both patients and HCPs should be aware of early signs of kidney issues.
About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.